Stuttgart - Delayed Quote EUR

Gimv NV (GI3.SG)

43.90

+0.30

(+0.69%)

At close: April 26 at 8:02 AM GMT+2

Key Events

Advanced Chart

Loading Chart for GI3.SG

9/21 12:03 PM

DELL

Previous Close 43.60
Open 44.10
Bid 44.30 x 10000
Ask 44.85 x 10000
Day's Range 44.10 - 44.10
52 Week Range 44.10 - 52.30
Volume 0
Avg. Volume 0
Market Cap (intraday) 1.223B
Beta (5Y Monthly) 0.53
PE Ratio (TTM) --
EPS (TTM) -2.20
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date Jul 3, 2023
1y Target Est --

Gimv NV is a private equity and venture capital firm specializing in direct and fund of funds investments. For direct investments, the firm specializes in buyouts, growth capital, middle market, debt, shareholder loans, seed, startups, early to mid-stage, late venture, public to private transactions, small and medium sized enterprises, later stage, mature, replacement capital, bridge financing, and recapitalization. Within fund of funds, it seeks to invest in venture capital and private equity funds. It seeks to invest in high performance growth companies that respond to that can speed up their internal growth through acquisitions. The firm typically invests in consumer 2020; Connected Consumer, fintech; health and care; smart industries; and sustainable cities. Within consumer 2020, it seeks to provide growth capital to emerging leaders. Within health and care platform, the firm seeks to invest in companies that can grow either organically or through a buy and build strategy. It mainly focuses on European market and midcap companies in Flanders and Brussels, and also invests in Kazakhstan, Benelux, Germany, France, Italy, Luxembourg, Netherlands, United Kingdom, Russia, Czech Republic, and Slovakia. Within consumer 2020, it focuses on consumer goods, food and beverage, healthy food, sport, convenience food, personal luxury, career, home & deco, baby & kids, pet products, retail, consumer services, media and content, travel and leisure, education, digital economy and online sectors. It invests in small and medium sized businesses primarily with headquarters in the Benelux, France, and Germany with an enterprise value of up to 125 million ($144.76 million). Within health and care sector, it focuses on life sciences, medtech, and health and care services. The firm focuses on biotech/biopharma comprising drugs, platform technologies, vaccines and diagnostic tests, preclinical, early clinical, and late clinical, medtech such as medical devices, consumables, IT and small equipment, and health and care services-based companies with headquarters in Benelux, France and DACH region. It also seeks to be an active shareholder, preferably lead or co-lead in its investments. Within smart industries, it focuses on equipment, services and tools for resource efficient development and production, automotive and aerospace, both optimizing of the existing and development of new means of transport, software and services harnessing the flexibility of the cloud, smart data management and advanced computation power, and components and systems for efficient use of energy, in terms of production, storage, management, use and transport sectors. It focuses on B2B products and services, based on innovation, advanced engineering, advanced manufacturing or software. It also makes flexible equity investment (equity, semi-equity, minority or majority) but always with a meaningful impact on the company and an exit trigger. Within sustainable cities, it focuses on Products, services and infrastructure for building sustainable urban societies: Utilities and consumer goods related to energy and other (raw) materials, Waste treatment, recycling and recovery, Construction and Infrastructure, Transport and Logistics Services, and biomass, green (sustainable) chemistry, water, offshore and maritime solutions and energy efficient infrastructure. It invests through (mezzanine, equity, minority or majority) but will always strive to have a meaningful impact on the company strategy and need an exit trigger. It also invests in semiconductors, chemicals, agriculture, clean technology, electronics, water processing and purification technologies. It seeks to invest in small to medium companies with headquarters in the Benelux, France and Germany (DACH) targeting an international customer base. For fund of fund investments, it seeks to invest in Europe. It seeks to invest between 2.5 million ($2.90 million) to 300 million ($425.44 million) with an enterprise value between $86.85 million and $868.55 million and sales value ranging from 5 million ($6.67 million) million to 400 million ($567.25 million). It typically makes investments between 3 million ($3.47 million) to 10 million ($11.58 million) in the biopharma and MedTech and between 10 million ($11.58 million) to 30 million ($34.74 million) in the health and care services. It may take a majority or a minority stake in its portfolio companies. Its investment horizon is between four and seven years. It also seeks a board seat in its portfolio companies. It invests with capital from its own balance sheet and through various funds under management. Gimv NV was founded on February 25, 1980 and is based in Antwerp, Belgium with additional offices in Paris, France; Hague, The Netherlands; Frankfurt am Main, Germany; London, United Kingdom; Prague, Czech Republic; Warsaw, Poland; and Munich, Germany.

www.gimv.com/en/